

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: HEIGHTMAN et al. Confirmation No.: 2093  
U.S. Serial No.: 10/599,636 Art Unit: 1624  
Filing Date: October 4, 2006 Examiner: Coleman, Brenda L  
Title: Tetrahydrobenzazepines as Histamine H3 Receptor Ligands

---

**COMMISSIONER FOR PATENTS**  
**P.O. Box 1450**  
**Alexandria, VA 22313-1450**

**LETTER**


Sir:

In the above-identified case, Applicant wants to make the US Patent Office aware of the following co-pending applications:

US Serial No.	US Filing Date	Attorney Docket No.
10/539,385	12/18/03	P33159
11/831,191	7/31/07	P33159 D1
12/339,145	12/19/08	P33159 D3
10/596,503	12/15/04	PB60626
10/598,759	3/10/05	PB60780
11/570,383	6/16/05	PB60910
11/573,732	8/12/05	PB61014

The following PCT cases of Applicant are also pending: WO 2008/104,598 and WO 2008/104,590.

Respectfully submitted,



Bonnie L. Deppenbrock  
Attorney for Applicant  
Registration No. 28,209

Date: 16 June 2009  
Customer No. 23347  
GlaxoSmithKline  
Corporate Intellectual Property  
Five Moore Drive  
P.O. Box 13398  
Research Triangle Park, NC 27709-3398  
Phone: 919-483-1577  
Facsimile: 919-483-7988

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : HEIGHTMAN, et al.  
Serial No. : 10/599,636  
Filing Date : October 4, 2006  
Title : TETRAHYDROBENZAZEPINES AS HISTAMINE H3 RECEPTOR LIGANDS  
  
Grp. /A.U. : 1624  
Examiner : Coleman, Brenda Libby  
Confirmation No. : 2093  
  
Docket No. : PB60825USw

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

- ☒ Copies of the following references are enclosed. **References 1-11**  
☐ Copies of the references were submitted in parent application Serial No. \_\_\_\_\_. (37 CFR 1.98(d))  
☐ A copy of the International Search Report which issued on International Application No. \_\_\_\_\_ is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

- A. ☐ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

- ☐ The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

- B. ☒ The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:  
(1) a final action under § 1.113 or  
(2) a notice of allowance under § 1.311,  
whichever occurs first.

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

- ☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).

- C. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. **[or]**
- ☐ Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and
- ☐ The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.

☒ Please charge any required fees to Deposit Account No. **07-1392**.

☐ A duplicate copy of this paper is attached.

Respectfully Submitted,

Bonnie L. Deppenbrock

Bonnie L. Deppenbrock, Attorney of Record  
Registration No. 28,209

Date: 16 June 2009  
GlaxoSmithKline  
Corporate Intellectual Property  
5 Moore Drive, P.O. Box 13398  
Research Triangle Park, NC 27709-3398  
Telephone: (919) 483-1577  
Facsimile: (919) 483-7988